PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Visiongain

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Pfizer will be the Leading Antibacterial Drug Manufacturer in 2012 with Revenue of $3.23Bn Says Visiongain Report - A new report by visiongain predicts that Pfizer will retain its position as the global leader in the antibacterial drugs market in 2012 - Visiongain.com
Pfizer will be the Leading Antibacterial Drug Manufacturer in 2012 with Revenue of $3.23Bn Says Visiongain Report

 

NewswireToday - /newswire/ - London, United Kingdom, 2012/06/26 - A new report by visiongain predicts that Pfizer will retain its position as the global leader in the antibacterial drugs market in 2012 - Visiongain.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

In that year, its seven leading antibiotics will achieve $3.23bn in revenue. However, patent expiries will cause Pfizer to lose antibacterial revenue between 2011 and 2016, as its market share falls to 6.7%. Those findings appear in Pharma Leader Series: Top 20 Antibacterial Drug Manufacturers 2012-2022, published in June 2012.

Visiongain’s analysis indicates that, in 2011, the top 20 antibacterial drug manufacturers accounted for 37.8% of that market. As well as Pfizer, other leading companies included Big Pharma players such as GSK, AstraZeneca and J&J, as well as acute care specialists, including Cubist Pharmaceuticals and ViroPharma. Many companies will experience falling market share in the coming 10 years, though. Patent expiries, generic competition and a relative lack of pipeline therapies will drive this decline.

Richard Lang, a pharmaceutical industry analyst in visiongain, said: “The antibacterial drugs market is highly fragmented and even many of the leading players rely on off-patent products for portions of their antibacterial revenue. Leading companies likely to see their market share grow in the future are those still taking an active interest in antibacterial drug development. Companies that have signed licensing deals for new products will also benefit.”

In 2017, the leading antibacterial drug, in terms of revenue, will be Cubist’s Cubicin (daptomycin). Revenue is forecast to grow strongly in the first half of the decade. Besides Cubist, other companies will benefit from this growth, including Novartis and Merck & Co., who both market the drug in certain territories. Companies with similar licensing deals for Optimer Pharmaceuticals’ C. difficile infection treatment, Dificid (fidaxomicin), will also benefit from rapid revenue growth. The C. difficile treatment market will become more crowded from 2012 to 2022, though, with a number of leading players targeting this submarket with pipeline drugs.

Visiongain’s report provides revenue forecasts to 2022 for the leading 20 companies in the antibacterial drugs sector. For each company, the report also contains:

• 2011 revenue analysis;
• A SWOT (strengths, weaknesses, opportunities and threats) analysis for the antibacterials division;
• Antibacterial R&D pipeline analysis.

Pharma Leader Series: Top 20 Antibacterial Drug Manufacturers 2012-2022 adds to visiongain’s range of Pharma Leader Series reports, assessing the prospects of leading companies in important pharmaceutical sectors. Visiongain is a business information provider based in London, UK.

For sample pages and further information concerning the visiongain report Pharma Leader Series: Top 20 Antibacterial Drug Manufacturers 2012-2022 please visit the website.

About visiongain
Visiongain (visiongain.com) is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Energy, Telecoms, Pharmaceutical, Defence, Aviation and Materials sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Visiongain

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Pfizer will be the Leading Antibacterial Drug Manufacturer in 2012 with Revenue of $3.23Bn Says Visiongain Report

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Sara Peerun - Visiongain.com 
+44(0)20 7336 6100 sara.peerun[.]visiongainglobal.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Visiongain securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Visiongain / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

First European Patients Treated with DC Bead LUMI™ Radiopaque Drug-Eluting Beads
FDA Approves Genentech’s Lucentis (Ranibizumab Injection) for Diabetic Retinopathy
Biopharmaceutical Analytical Instrumentation Market Garners Strong Opportunities from Double-digit Growth in Biosimilars Finds Frost & Sullivan
BD Completes Acquisition of Caesarea Medical Electronics
MDxHealth and Ghent University Ink Licensing and Collaboration Agreements to Develop Cancer Biomarker Visualization Technology
Ipsen Completes Acquisition of ONIVYDE® (irinotecan liposome injection) and Additional Oncology Assets from Merrimack Pharmaceuticals
FDA Grants Breakthrough Therapy Designation for Rituxan® (Rituximab) in Pemphigus Vulgaris
MDxHealth Signs Agreement with Lab21 to Make SelectMDx Liquid Biopsy Test Available in the United Kingdom
Greenphire Drives Global Site Adoption of Clinical Trial Payment Solutions
Ipsen Announces MHRA Approval of New Indication for Decapeptyl® for the Treatment of Pre-menopausal Women with Early Stage Breast Cancer
SelectMDx Chosen by Michigan Medicine as Pre-biopsy Diagnostic Tool in Groundbreaking US Prostate Cancer Risk Clinic
BTG Announces CE Mark Certification for DC Bead LUMI™ - The First Commercially Available Radiopaque Drug-Eluting Bead
Sartorius to Acquire Real-time Live-cell Analysis Pioneer and Leader Essen BioScience
Pyxis™ ES System to Help U.S. Department of Defense Advance Medication Safety and Patient Care
BTG Receives U.S. FDA 510(k) Clearance for EKOS® Control Unit 4.0

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  MagLar, Inc.

Visit  JobsWare.com





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)